Catherine Desmond

Catherine Desmond

Auto-generated profile, based on publicly available information

Catherine Desmond

Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
CDChristopher E Dandoy
Christopher E Dandoy
SRSeth Rotz
Seth Rotz
PAPriscila Badia Alonso
Priscila Badia Alonso
AKAnna Klunk
Anna Klunk
CDCatherine Desmond
Catherine Desmond
SJSonata Jodele
Sonata Jodele
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence of TA-TMA is much higher than prior retrospective studies that did not systematically screen. These data have not been replicated in a multicenter study. Our objective was to determine the incidence and risk factors for TA-TMA and compare outcomes of pediatric HSCT patients with and without TA-TMA. Patients were prospectively screened for TA-TMA at participating centers using a simple to implement and inexpensive strategy from the start of the preparative regimen through day +100. TA-TMA was diagnosed if ≥4 of 7 laboratory/clinical markers diagnostic for TA-TMA were present concurrently or if tissue histology showed TA-TMA. A total of 614 patients (359 males; 58%) received prospective TA-TMA screening at 13 pediatric centers. TA-TMA was diagnosed in 98 patients (16%) at a median of 22 days (interquartile range, 14-44) posttransplant. Patients with TA-TMA had significantly increased bloodstream infections (38% [37/98] vs 21% [107/51], P ≤ .001), mean total hospitalization days (68; 95% confidence interval [CI], 63-74 vs 43; 95% CI, 41-45; P ≤ .001), and number of days spent in the intensive care unit (10.1; 95% CI, 6.4-14; vs 1.6; 95% CI, 1.1-2.2; P ≤ .001) in the first 100 days after HSCT compared with patients without TA-TMA. Overall survival was significantly higher in patients without TA-TMA (93%; 490/516) compared with patients with TA-TMA (78%; 76/98) (P ≤ .001). These data support the need for systematic screening for TA-TMA and demonstrate the feasibility and efficacy of an easy to implement strategy to do so.

10 May 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RPRachel Phelan
Rachel Phelan
SRSeth Rotz
Seth Rotz
CDChristopher E. Dandoy
Christopher E. Dandoy
JAJeffery J. Auletta
Jeffery J. Auletta
PBPriscila Badia
Priscila Badia
DHDavid M Hartley
David M Hartley
Hematopoietic stem cell transplantation (HSCT) is a life-saving yet complex treatment for pediatric patients that introduces significant physical, emotional, and logistical challenges for caregivers. This multicenter, prospective qualitative longitudinal study explored caregiver experiences across four time points: pre-transplant (n=47), 30 days post-transplant (n=43), 100 days post-transplant (n=34), and six months post-transplant (n=26). Forty-nine caregivers participated in semi-structured interviews, which were transcribed and thematically analyzed. This manuscript encompasses the following themes that emerged from the interviews: treatment-related side effects and complications, communication gaps, and the impact of the COVID-19 pandemic. Caregiver priorities evolved over time, shifting from managing acute complications such as pain, infections, mucositis, and medication administration to addressing longer-term concerns like developmental delays, nutritional rehabilitation, and psychosocial adaptation. Caregivers reported challenges such as information overload, inconsistent messaging, and limited preparation for transitions in care. They employed various strategies to cope, including advocacy, peer support, and the use of healthcare team resources. These findings highlight the importance of stage-specific, tailored interventions to support caregivers throughout the HSCT journey. Clear communication, accessible education, and coordinated multidisciplinary care are essential to fostering caregiver resilience and improving patient and family-centered outcomes.

21 April 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
NBNeel S. Bhatt
Neel S. Bhatt
LLLeslie Lehmann
Leslie Lehmann
CDChristopher E Dandoy
Christopher E Dandoy
JAJeffery J. Auletta
Jeffery J. Auletta
PBPriscila Badia
Priscila Badia
SRSeth Rotz
Seth Rotz